iRhythm Reports Strong Q4 Earnings Growth Amid Market Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Source: stocktwits
iRhythm Holdings, Inc. shares fell 3.81% and hit a 20-day low despite the Nasdaq-100 rising 0.99% and the S&P 500 increasing 0.66%.
The company reported a strong Q4 2025 earnings growth, with revenue of $208.9 million, a 27.1% year-over-year increase, and a net income of $5.6 million, marking its first positive quarterly net income. iRhythm also expects 2026 revenue to range between $870 million and $880 million, reflecting confidence in sustained growth and profitability. However, the stock's decline is attributed to sector rotation, as broader market strength did not translate to gains for iRhythm.
This performance highlights iRhythm's solid market position and growth potential in the cardiac monitoring sector, but the stock's current trajectory suggests a disconnect between company performance and market sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRTC
Wall Street analysts forecast IRTC stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 108.840
Low
205.00
Averages
222.00
High
244.00
Current: 108.840
Low
205.00
Averages
222.00
High
244.00
About IRTC
iRhythm Holdings, Inc. is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. The Company's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The Company provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
iRhythm Addresses Cybersecurity Incident Impact
- Cybersecurity Incident Overview: iRhythm Holdings detected suspicious activity on June 8 involving its third-party-hosted business applications, prompting the initiation of its cybersecurity response plan; despite the material volume of potentially leaked information, the company reports no substantial impact on its business operations.
- Ransom Demand from Threat Actor: Following the incident, a threat actor demanded payment to prevent the disclosure of sensitive information, including patient data; however, iRhythm confirmed that its clinical or medical device systems were unaffected, ensuring customer safety.
- Financial Impact Assessment: iRhythm emphasized that while the volume of potentially leaked information is significant, the presence of cybersecurity insurance means the incident is unlikely to materially affect its financial position or operating results, thereby maintaining investor confidence.
- Future Outlook: iRhythm forecasts revenue for 2026 to be between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, demonstrating the company's resilience and growth potential in the face of challenges.
See More
iRhythm Holdings Reports Cyber Attack Incident
- Cyber Attack Incident: iRhythm Holdings reported unauthorized activity involving data on third-party applications last week; however, the company stated that it has not identified any impact on products, patient safety, or medical device systems, demonstrating its resilience in data security.
- Data Security Measures: The company emphasized in its filing that despite the cyber attack, its existing data protection measures effectively prevented potential threats to critical medical devices and patient information, indicating the effectiveness of its investments in cybersecurity.
- Impact Assessment: iRhythm Holdings has not found any product defects or patient safety issues related to the cyber attack, providing some reassurance to investors and showcasing the company's crisis management capabilities.
- Future Outlook: Although the incident did not cause direct impacts, the company may strengthen its cybersecurity strategies to prevent similar occurrences in the future, thereby further protecting patient data and enhancing its corporate reputation.
See More
iRhythm Gains CDC Coverage Decision for Cardiac Monitoring Devices
- Policy Boost: The CDC's finalized local coverage determination for cardiac monitoring devices, including iRhythm's Zio ECG system, is expected to enhance market acceptance and sales potential for the company.
- Analyst Optimism: BTIG analyst Marie Thibault highlighted in a research note that this decision alleviates investor confusion regarding Medicare proposals, viewing the update as a positive for iRhythm with a Buy rating and a target price of $185.
- Market Expectations: The analyst anticipates that the other two Medicare Administrative Contractors (MACs), Palmetto and CGS, will follow suit, further strengthening iRhythm's competitive position and business stability in the market.
- Financial Outlook: iRhythm forecasts 2026 revenue between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, indicating strong growth potential supported by the new policy.
See More
iRhythm Exceeds Q1 2026 Earnings Expectations
- Significant Revenue Growth: iRhythm reported $199.4 million in revenue for Q1 2026, representing a 26% year-over-year increase that exceeded analyst expectations, demonstrating strong performance across cardiology and primary care, thereby solidifying its market position.
- Improved Adjusted EBITDA: The adjusted EBITDA margin for Q1 improved to 7.1%, reflecting an 880 basis point increase from the previous quarter, which highlights the company's success in manufacturing automation and workflow optimization, and is expected to drive future profitability enhancements.
- Market Expansion Strategy: The company achieved its best quarter in history in the U.K. while also receiving an updated reimbursement framework in Japan, indicating that its international market expansion strategy is yielding results and is likely to enhance revenue streams in the future.
- Optimistic Outlook: iRhythm raised its full-year 2026 revenue guidance to $875 million to $885 million and anticipates Q2 revenue in the range of $218 million to $220 million, reflecting management's confidence in future performance and sustained market demand.
See More
iRhythm Technologies Set to Announce Q1 Earnings on April 30
- Earnings Announcement: iRhythm Technologies is set to release its Q1 2023 earnings on April 30 after market close, with a consensus EPS estimate of -$0.64, reflecting a 32.6% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $194.09 million, representing a 22.3% year-over-year increase, which highlights the company's positive performance in market demand and product innovation, potentially driving future growth.
- Historical Performance Review: Over the past two years, iRhythm has exceeded EPS estimates 50% of the time and revenue estimates 100% of the time, demonstrating the company's reliability and execution capability in financial forecasting.
- Future Outlook: iRhythm aims for a revenue target of $870 million to $880 million by 2026 while continuing to expand its innovations in artificial intelligence and mobile cardiac telemetry (MCT), showcasing the company's confidence and strategic positioning for future growth.
See More
Ventripoint Joins Global Congenital Heart Disease Alliance to Enhance Care Access
- Growing Market Demand: The 2026 World Heart Report indicates that congenital heart disease now affects approximately 16 million people globally, up from 11.8 million three decades ago, highlighting the urgent need for advanced diagnostic technologies, particularly in low-income regions.
- Technological Innovation: Ventripoint's VMS+™ platform utilizes artificial intelligence to convert standard 2D echocardiograms into highly accurate 3D heart models, delivering MRI-level measurement accuracy to address the limitations of traditional imaging techniques in complex anatomical structures.
- Global Collaboration: Ventripoint announced its support for the newly formed Global Congenital Heart Disease Alliance (GCHDA) and plans to provide four VMS+™ units to directly support congenital heart disease patients, thereby expanding access to advanced diagnostic care.
- Broad Market Prospects: The echocardiography market is projected to reach approximately $2.64 billion by 2030, positioning Ventripoint favorably in the rapidly growing medical technology sector, especially as AI-driven cardiac imaging technologies gain increasing attention.
See More
iRhythm Addresses Cybersecurity Incident Impact
- Cybersecurity Incident Overview: iRhythm Holdings detected suspicious activity on June 8 involving its third-party-hosted business applications, prompting the initiation of its cybersecurity response plan; despite the material volume of potentially leaked information, the company reports no substantial impact on its business operations.
- Ransom Demand from Threat Actor: Following the incident, a threat actor demanded payment to prevent the disclosure of sensitive information, including patient data; however, iRhythm confirmed that its clinical or medical device systems were unaffected, ensuring customer safety.
- Financial Impact Assessment: iRhythm emphasized that while the volume of potentially leaked information is significant, the presence of cybersecurity insurance means the incident is unlikely to materially affect its financial position or operating results, thereby maintaining investor confidence.
- Future Outlook: iRhythm forecasts revenue for 2026 to be between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, demonstrating the company's resilience and growth potential in the face of challenges.
See More
iRhythm Holdings Reports Cyber Attack Incident
- Cyber Attack Incident: iRhythm Holdings reported unauthorized activity involving data on third-party applications last week; however, the company stated that it has not identified any impact on products, patient safety, or medical device systems, demonstrating its resilience in data security.
- Data Security Measures: The company emphasized in its filing that despite the cyber attack, its existing data protection measures effectively prevented potential threats to critical medical devices and patient information, indicating the effectiveness of its investments in cybersecurity.
- Impact Assessment: iRhythm Holdings has not found any product defects or patient safety issues related to the cyber attack, providing some reassurance to investors and showcasing the company's crisis management capabilities.
- Future Outlook: Although the incident did not cause direct impacts, the company may strengthen its cybersecurity strategies to prevent similar occurrences in the future, thereby further protecting patient data and enhancing its corporate reputation.
See More
iRhythm Gains CDC Coverage Decision for Cardiac Monitoring Devices
- Policy Boost: The CDC's finalized local coverage determination for cardiac monitoring devices, including iRhythm's Zio ECG system, is expected to enhance market acceptance and sales potential for the company.
- Analyst Optimism: BTIG analyst Marie Thibault highlighted in a research note that this decision alleviates investor confusion regarding Medicare proposals, viewing the update as a positive for iRhythm with a Buy rating and a target price of $185.
- Market Expectations: The analyst anticipates that the other two Medicare Administrative Contractors (MACs), Palmetto and CGS, will follow suit, further strengthening iRhythm's competitive position and business stability in the market.
- Financial Outlook: iRhythm forecasts 2026 revenue between $875 million and $885 million, targeting an adjusted EBITDA margin of 12%-13%, indicating strong growth potential supported by the new policy.
See More
iRhythm Exceeds Q1 2026 Earnings Expectations
- Significant Revenue Growth: iRhythm reported $199.4 million in revenue for Q1 2026, representing a 26% year-over-year increase that exceeded analyst expectations, demonstrating strong performance across cardiology and primary care, thereby solidifying its market position.
- Improved Adjusted EBITDA: The adjusted EBITDA margin for Q1 improved to 7.1%, reflecting an 880 basis point increase from the previous quarter, which highlights the company's success in manufacturing automation and workflow optimization, and is expected to drive future profitability enhancements.
- Market Expansion Strategy: The company achieved its best quarter in history in the U.K. while also receiving an updated reimbursement framework in Japan, indicating that its international market expansion strategy is yielding results and is likely to enhance revenue streams in the future.
- Optimistic Outlook: iRhythm raised its full-year 2026 revenue guidance to $875 million to $885 million and anticipates Q2 revenue in the range of $218 million to $220 million, reflecting management's confidence in future performance and sustained market demand.
See More
iRhythm Technologies Set to Announce Q1 Earnings on April 30
- Earnings Announcement: iRhythm Technologies is set to release its Q1 2023 earnings on April 30 after market close, with a consensus EPS estimate of -$0.64, reflecting a 32.6% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $194.09 million, representing a 22.3% year-over-year increase, which highlights the company's positive performance in market demand and product innovation, potentially driving future growth.
- Historical Performance Review: Over the past two years, iRhythm has exceeded EPS estimates 50% of the time and revenue estimates 100% of the time, demonstrating the company's reliability and execution capability in financial forecasting.
- Future Outlook: iRhythm aims for a revenue target of $870 million to $880 million by 2026 while continuing to expand its innovations in artificial intelligence and mobile cardiac telemetry (MCT), showcasing the company's confidence and strategic positioning for future growth.
See More
